| Literature DB >> 24415999 |
Thierry Chataigneau1, Damien Lemoine1, Thomas Grutter1.
Abstract
P2X receptors are ATP-gated non-selective cation channels involved in many different physiological processes, such as synaptic transmission, inflammation, and neuropathic pain. They form homo- or heterotrimeric complexes and contain three ATP-binding sites in their extracellular domain. The recent determination of X-ray structures of a P2X receptor solved in two states, a resting closed state and an ATP-bound, open-channel state, has provided unprecedented information not only regarding the three-dimensional shape of the receptor, but also on putative conformational changes that couple ATP binding to channel opening. These data provide a structural template for interpreting the huge amount of functional, mutagenesis, and biochemical data collected during more than fifteen years. In particular, the interfacial location of the ATP binding site and ATP orientation have been successfully confirmed by these structural studies. It appears that ATP binds to inter-subunit cavities shaped like open jaws, whose tightening induces the opening of the ion channel. These structural data thus represent a firm basis for understanding the activation mechanism of P2X receptors.Entities:
Keywords: ATP; P2X receptors; binding site; crystal structure; engineered site-directed labeling; gating; mutagenesis
Year: 2013 PMID: 24415999 PMCID: PMC3874471 DOI: 10.3389/fncel.2013.00273
Source DB: PubMed Journal: Front Cell Neurosci ISSN: 1662-5102 Impact factor: 5.505
Figure 1Crystal structure of zfP2X4 receptor bound to ATP. (A) Lateral view of the trimeric structure. Each subunit, displayed in both surface and ribbon representation, is shown in a different color. Only one bound ATP molecule is shown. (B) Close-up view of the ATP-binding site. The oxygen atom from the solvent molecule (glycerol) is shown in sphere representation. Black dashed lines indicate hydrogen bonding. (Modified from Hattori and Gouaux, 2012).
Effects of mutations on ATP-induced activation of P2X receptors.
| hP2X1 | Positively charged residues | K190A | 5-fold | Ennion et al., | |
| K70A and K70R | 5-fold and 18-fold, respectively | ||||
| R292K and R292A | 90–120-fold | ||||
| K309R and K309A | 25-fold and 1400-fold, respectively | ||||
| K68A | >1800-fold | ||||
| K68R | Non-functional | ||||
| Polar residues | T186A | 6-fold | Roberts and Evans, | ||
| N290A | 60-fold | ||||
| Aromatic residues | F185A | 10-fold | Roberts and Evans, | ||
| F291A | 160-fold | ||||
| Glycine residues | G71A | 6-fold | Digby et al., | ||
| G96A | E98 | Non-functional | |||
| G250A (plus G250P, G250C, G250D, G250F, G250I, G250K, and G250N but not G250S) G301A (but not G301P or G301C) | |||||
| Proline residues | P272A (but not P272F, P272G, or P272I) | Non-functional | Roberts and Evans, | ||
| Cysteine residues | C217A | 8-fold | Ennion and Evans, | ||
| C227A | 45-fold | ||||
| E181 to V200 segment | K190C | 5-fold | Roberts et al., | ||
| F188C | 7.5-fold | ||||
| T186C | 8-fold | ||||
| S286 to I329 segment | G288C, F297C, F311C | G294, Y303, Y318 | 5–10-fold | Roberts and Evans, | |
| R292C | 17-fold | ||||
| F291C | 50-fold | ||||
| N290C | 71-fold | ||||
| K309C | 195-fold | ||||
| E52 to G96 segment | K70C | 10-fold | Allsopp et al., | ||
| F92C | I94 | 100-fold | |||
| K68C | >3000-fold | ||||
| rP2X1 | Residue in the first intercysteine region (segment A118 to I125) | E122C | Not aligned | 10-fold | Lorinczi et al., |
| Positively charged residues | K68A | Non-functional | Wilkinson et al., | ||
| hP2X2 | F183C, T184C, F289C | 4–10-fold | Roberts et al., | ||
| N288C, R290C, | Major decrease in ATP potency | ||||
| K69C, K71C | Non-functional | ||||
| rP2X2 | Positively and negatively charged residues; polar residues | D259A, K71A, Q108A, T184A, K188A, N288A, R290A, R304A | D265 | Major decrease in ATP potency | Jiang et al., |
| K69A, K308A | Non-functional | ||||
| Glycine residues | G247A | Non-functional | Nakazawa and Ohno, | ||
| G248V (but not G248A) | |||||
| Cysteine residues | C113A, C124A, C130A, C147A, C158A, C164A, C214A | 9–30-fold Non-functional | Clyne et al., | ||
| C224A | |||||
| D57 to K71 segment | K71C | 1000-fold | Jiang et al., | ||
| K69C | Non-functional | ||||
| E84C, Q138C | A90, R143 | Potentiation of ATP potency | Jiang et al., | ||
| E85C, F183C, F291C, A309C, Y310C, T184C, L306C | E85C, | 5–12-fold | |||
| G139C, Y287C G141C, L186C | Major decrease in ATP potency (>25-fold) | ||||
| N288C, F289C, R290C | |||||
| K69C, K71C, K308C | Non-functional | ||||
| hP2X3 | Residues in nucleotide binding domains (NBD-1-4) | F174A, K284A K65A, G66A T172A, N279A, F280A | Reduction of α,β-methylene potency | Bodnar et al., | |
| K63A, K176A, R281A, | Abolition of α,β-methylene-induced currents | ||||
| Conserved positively charged residues | K65A | 12-fold (α,β-methylene potency) | Fischer et al., | ||
| R281A | 60-fold | ||||
| K63A, K176A, R295A, K299A | Non-functional | ||||
| rP2X2/3 | Positively charged residues | rP2X2 (K69A) | Non-functional | Wilkinson et al., | |
| rP2X2 (K308A) | |||||
| rP2X3 (K299A) | |||||
| rP2X3 (K63A) | |||||
| rP2X2 (K69A + K308A) | Functional receptor | ||||
| rP2X2 (K69A) + rP2X3 | No modification of α,β-methylene potency | ||||
| rP2X2 (K308A) + rP2X3 | Slight decrease of α,β-methylene potency | ||||
| rP2X2 + rP2X3 (K63A) | Major decrease of α,β-methylene potency | ||||
| rP2X2 + rP2X3 (K299A) | |||||
| rP2X2 (K69A + K308A) + rP2X3 | |||||
| rP2X4 | Charged and aromatic residues | F294A | 8-fold | Zemkova et al., | |
| F230A (but not F230W or F230Y), R278A (but not R278K), D280A (but not D280E) | F233 R281 D283 | Non-functional | |||
| K67A (and K67R), F185A (but not F185W), K190A (but not K190R), R295A (and R295K), K313A (and K313R) | |||||
| K180 to K326 segment | R318A (but not R318K) | R321 | 20-fold | Yan et al., | |
| K190A (but not K190R), F230A (but not F230W), R278A (but not R278K), D280A and D280Q (but not D280E) | >1666-fold | ||||
| K313 to I333 | G316S | G319 | 9-fold | Yan et al., | |
| Y315A, G316A (but not G316P), R318A | Y318, G319 R321 | >16-fold | |||
| K313A | 10,000-fold | ||||
| K313R | Major decrease (value not indicated) | ||||
| F185C | 20-fold | Roberts et al., | |||
| T186C | 50-fold | ||||
| K67C, K69C, | Major decrease in ATP potency | ||||
| R295C, K313C | |||||
| hP2X7 | K193A, K311A | Non-functional | Worthington et al., | ||
| DdP2X | K67A | >10-fold | Fountain et al., | ||
| K289A | Major decrease | ||||
| D330A | Non-functional |
The results have been classified according to an increasing rank of order of inhibition for the mutations indicated in each study.
For the corresponding residues in the zfP2X4 crystal structure:
− conserved residues are in bold;
− underlined residues have been identified to participate to the binding of ATP;
− normal characters indicate residues that are not conserved among species.
The modification of α,β-methylene potency is also indicated. Decrease of agonist potency not exceeding 5-fold has not been taken into account.
The lack of function of G250A-containing hP2X1 receptors most likely results from a failure in normal processing of the receptor (Digby et al., 2005). K307C-containing hP2X2 receptors were expressed at lower levels in cells (Roberts et al., 2008). R295A-, and K299A-containing hP2X3 receptors were expressed at lower levels in cells (Bodnar et al., 2011). F230A-containing rP2X4 receptors were expressed at lower levels (Zemkova et al., 2007). A reduction of trafficking of N293C-containing rP2X4 receptors to the cell surface has been proposed (Roberts et al., 2008).
Figure 2Mapping in the zfP2X4 receptor of residues identified by site-directed mutagenesis. Corresponding residues (indicated in red spheres) previously identified by site-directed mutagenesis in different P2X receptor subtypes (see Table 1) are mapped on the crystal structure of the zfP2X4 receptor. The ATP molecule is shown in stick representation. Note that only few residues contact (in orange) the ATP molecule. Oxygen, nitrogen, and sulfur atoms are colored, respectively, in light red, blue, and yellow. Hidden residues are indicated in magenta.
Figure 3Alternative methods to identify residues involved in the ATP-binding of P2X receptors. (A) Principle of engineered affinity labeling strategy. Chemical structures of the affinity label NCS-ATP and cysteine are shown. (B) Sequence alignment of identified segments containing NCS-ATP-labeled residues in the P2X2 receptor (N140 and L186). (C) Spatial location of the corresponding labeled residues in the X-ray structure of the ATP-bound zfP2X4 receptor.
Figure 4Plausible mechanism of ATP-gated P2X receptors activation. The sequential steps leading to pore opening are indicated.